THE MODERN BIOHEALTH, WITH PERSPECTIVE.
Clinician-led care in Florida

PEPTIDE ATLAS / MUSCLE & RECOVERY / TB-500

EvidenceInsufficient
Evidence is not sufficient to establish the claims discussed.
RegulatoryNot FDA-approved
No FDA-approved product for the use discussed. Research interest is not evidence of safe routine treatment.
Corrections & editorial standards

TB-500

Editorial visualization for muscle & recovery peptide research
THE SIGNAL MAP · MUSCLE & RECOVERY
ALSO KNOWN ASThymosin beta-4 fragment · LKKTETQ

A thymosin beta-4 fragment with reported human use but no established healing or performance benefit.

01CATEGORYMuscle & recovery
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTECommonly marketed for subcutaneous or intramuscular injection; neither is approved
04REVIEW STANDARDProduct, indication and evidence

HOW TO USE THIS PAGE

Read the profile in the order that protects the decision.

  1. 01
    Verify what it is

    Confirm the exact molecule, route, regulatory lane and actual human evidence.

  2. 02
    Read the evidence limits

    Unsupported claims, contraindications and uncertainty come before any protocol.

  3. 03
    Build the monitoring plan

    Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.

IMPORTANT STATUS CHECK

This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.

RESEARCH PASSPORT

The five facts to know first.

HUMAN EVIDENCEInsufficient

Evidence strength for the context described on this page.

REGULATORY LANENot FDA-approved

Status is product-, formulation- and indication-specific.

CLINICAL CONTEXTIndividual evaluation required

Public education does not establish a personal treatment plan.

SOURCE PACK3 direct source links

Plus 1 research searches. A search link is not a cited study or proof of a claim.

TESTED ATHLETESVerify the exact ingredient.

Peptide hormones, growth factors and related substances may be prohibited.

Check Global DRO ↗
Know the review boundary.

Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.

How we describe evidence →

OVERVIEW

What TB-500 is.

TB-500 usually refers to the short LKKTETQ fragment, not pharmaceutical-grade full-length thymosin beta-4. Results from one molecule should not be casually assigned to the other.

HOW IT IS THOUGHT TO WORK

Marketed around actin regulation, cell migration, blood-vessel formation and wound repair; clinical translation is unestablished.

REGULATORY SOURCE CHECK · November 8, 2026

The October 2026 HHS appendix specifies TB-500 acetate in subcutaneous or intramuscular injectable forms. Its conditional policy requires defined identity, quality controls and patient-specific prescriptions. The Federal Register describes it as draft and nonbinding. It is not FDA approval, a final 503A listing, or proof of safety or effectiveness, and does not establish Modern Bio access.

Read the HHS identity, route and policy conditions ↗

This checks the stated regulatory point only, not every clinical claim in the profile.

EFFECTS & EVIDENCE

What the evidence supports—and what it does not.

SUPPORTED IN CONTEXT
  • No established human healing or performance benefit for TB-500
NOT ESTABLISHED
  • Tendon, ligament or muscle regeneration
  • Faster return to sport
  • Safety of repeated injection
  • Equivalence to thymosin beta-4 studied in research
RESEARCH UPDATE · November 8, 2026Reported use is not the same as reliable clinical evidence.

FDA’s safety-risk page reports no identified human-exposure data for TB-500 drug products. HHS’s October 2026 Appendix B describes documented historical compounded use. These are different records: reported use does not establish clinical benefit, comprehensive safety or a validated regimen. Human studies of full-length thymosin beta-4 cannot establish the fragment’s benefits.

Read HHS Appendix B alongside the FDA safety assessment ↗

Evidence grade: Insufficient. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.

CLINICAL CONTEXT

The decision is individual.

Research interest does not establish an approved treatment, a safe personal regimen or reliable product quality. Discuss established alternatives with a qualified clinician.

What is the exact claim?

Identify the outcome, formulation and population actually studied.

What would change the decision?

Review benefits, uncertainty, contraindications and better-studied alternatives.

Who owns follow-up?

A treatment decision needs a responsible clinician, monitoring and a review date.

This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.

MONITORING

What should be tracked.

  • No validated monitoring program
  • Injury-specific rehabilitation and clinical reassessment remain the standard

SAFETY

Risks, red flags and reasons to avoid it.

KNOWN OR PLAUSIBLE RISKS
  • Immunogenicity and peptide impurities
  • Unknown systemic effects
  • Contamination and sterility failures
  • Potential anti-doping consequences for competitive athletes
AVOID / ESCALATE
  • Self-injection
  • Active cancer or unexplained mass
  • Pregnancy
  • Using it in place of rehabilitation
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.

CLINICIAN VISIT CHECKLIST

Six questions worth bringing with you.

01What exact product is this?

Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.

02What outcome are we treating?

Name the diagnosis or target, how it will be measured and the realistic time to reassess.

03Why this option?

Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.

04Where did the dose come from?

Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.

05What is the monitoring plan?

Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.

06How is quality verified?

Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.

Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.

SOURCES & RESEARCH LINKS

Read the record yourself.

We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.

PRODUCTS & TREATMENT ACCESS

There is no product we can responsibly recommend.

AVAILABILITY

Not FDA-approved. An October 2026 HHS draft, nonbinding policy describes conditional enforcement discretion for specified compounded products. It does not establish approval, safety, effectiveness or availability through Modern Bio. See the dated regulatory note and official source.

MARKET REALITY

Sellers frequently blur full-length thymosin beta-4 and its fragment. That is a scientific and product-identity problem, not a minor naming issue.

NO COMMERCE RECOMMENDATION

Evidence before affiliate revenue.

We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.

Explore evidence-backed options →

NEXT STEP

Return to muscle & recovery peptides.

Explore the category →

YOUR NEXT STEP

Ready for a clinician-led plan?

Clinical review determines the appropriate next step. No treatment is guaranteed.

THE CARE PATH

  1. We order your labs

  2. A licensed clinician reviews results and recommends a plan

  3. Rx sent directly to you when appropriate

Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.

Start your lab reviewExplore free educational tools